CVS Health Corporation (CVS)

CVS Health reported third-quarter adjusted earnings of $2.09 per share on November 4, 2026, against an analyst estimate of $1.65, a beat of 26.67%. The stock rose 1.71% in the first session after that report, and it has gained 11.96% over the past week. Since then, three firms have reiterated positive ratings: UBS twice, on November 5 and November 6, Barclays and Leerink Partners on November 5. The move leaves the stock trading at $89.52, just above its 200-day average and just below its 50-day average, so the price is caught between two trend signals rather than clearly trending either way. The bigger question for investors is whether the earnings strength reaches the share price. CVS trades at a trailing P/E of 10.40 against a sector median of 31.9, a large discount that reflects thin margins and a stock that has lagged over six months. Whether that discount narrows will depend on the company continuing to beat expectations.

CVS reported adjusted earnings of $2.09 per share on November 4, 2026, against an analyst estimate of $1.65, a beat of 26.67%. The stock rose 1.71% in the first session after the report. That reaction was positive, but it was modest compared with the size of the beat, and the stock has since traded in a narrow band around $89. Across the eight reports, the stock rose in the first session five times and fell three times, so a beat has not reliably lifted the shares on its own. Investors have been looking to the outlook and the valuation discount rather than the headline beat alone.

At $89.52, the stock trades at a trailing P/E of 10.40, which is 67.4% below the sector median P/E of 31.9. Its price-to-sales ratio of 0.27 compares with a sector median of 3.4. Reported earnings per share over the last twelve months were $8.61, which gives the low P/E its basis. The profit margin is thin, at 1.18% net and 3.06% operating, so the stock's valuation reflects low margins rather than a shortage of earnings. Return on equity of 14.36% is above the sector median of 7.3%, and debt-to-equity is 0.93.

Of 28 analysts with a current rating, 25 rate CVS a buy or strong buy, three hold it, and none sell it. Three months ago, 24 of 27 ratings were buy. The median 12-month price target is $110.00, which is 22.9% above the price, and the range runs from $86.00 to $146.00. The lowest target sits just below the current price. Among the recent actions, UBS kept its Buy rating on November 5 and again on November 6, and Barclays kept its Overweight rating on November 5.

Over the last 18 months, insiders sold shares worth $324.2M across three sales and bought shares worth $100K in one open-market purchase. Insider sales are often planned in advance or made to cover tax on vesting shares, so they carry less weight than open-market buying. The purchase is small relative to the sales.

The base case is that CVS holds its current range while the trend signals resolve. The price sits just above the 200-day average of $89.02 and just below the 50-day average of $89.97, so a sustained move above the 50-day average would strengthen the recovery picture, while a slip back below the 200-day average would weaken it. Earnings have beaten estimates in all eight recent reports, and analysts expect fiscal 2026 EPS to grow 21.7% to $8.22, though they expect only 4.7% growth to $8.61 in fiscal 2027. That slower forward growth is a key reason the analysts' median target of $110.00 sits 22.9% above the price rather than higher. The case would improve if the company keeps beating estimates and the price clears the 50-day average with conviction, moving toward the analysts' target range. It would weaken if revenue growth, which was 7.26% in the latest quarter and slightly slower than the sector median of 8.1%, fades, or if the three-month decline of 5.49% resumes. Analyst targets run from $86.00 to $146.00, so the spread of views is wide.

Support sits at the 200-day simple moving average of $89.02, the nearest level below the price, followed by the 20-day exponential moving average of $88.35. Further below, the 52-week low of $69.51 marks the bottom of the one-year range and would be the next key floor if the stock weakened materially. Resistance begins at the 50-day simple moving average of $89.97, which is the nearest level above the price and the first hurdle for a rebound. Beyond it, the 52-week high of $110.68 is the level a sustained advance would have to reach next.